Medication Resistant Epilepsy

A practical yet comprehensive review of the underlying causes of medication-resistant epilepsy and effective forms of treatment.

This book gives an exhaustive account of the classification and management of epileptic disorders. It provides clear didactic guidance on the diagnosis and treatment of epileptic syndromes and seizures through thirteen chapters, complemented by a pharmacopoeia and CD ROM of video-EEGs.

The pharmacological fight against epilepsy began many centuries ago when Hippocrates discovered that the cause of epilepsy is natural, as opposed to supernatural and, as a consequence, must be treated with a natural remedy. Even though science has significantly progressed since that era, the challenge to find remedies for epilepsy is ever present. The aim of this particular volume is to offer an up-to-date review of the most recent advances in antiepileptic drug development, considered from various viewpoints: (i) general, by taking into account the size of refractory epilepsy and its related problems; (ii) experimental, by exploring the mechanisms of epileptogenesis and the possiblility of influencing it through drugs, and (iii) clinical, by describing the results obtained with compounds currently at an advanced stage of testing.

Epilepsy in pregnancy poses a serious threat to the mother and to her developing child. Even in previously well-controlled epilepsy, physiological changes in the mother during pregnancy and also during labour and delivery can alter the pharmacokinetic drug (AED) therapy causing increased seizure frequency.

Highly Commended at the British Medical Association Book Awards 2016 The Treatment of Epilepsy, fourth edition, is a comprehensive reference and clinical guide to the pharmacological, medical and surgical options available in the treatment of epilepsy. The text is compiled by a group of internationally renowned editors and contributors and is now in full color and extensively illustrated The first two sections cover the background to, and principles of, treatment in different clinical situations Section three comprises a series of systematic reviews of contemporary drug therapy, devoting one chapter to each anti-epileptic drug and covering all clinically-relevant aspects Section four focuses on the surgical options, devoting individual chapters to each of the modalities of presurgical assessment and to each surgical operation or approach This 4th edition is extensively revised incorporating the many recent developments in therapy, and comprises 81 chapters from world experts from 18 countries

Over 12 million people with epilepsy have seizures that cannot be controlled by antiepileptic drugs. The term "drug-resistance" is abundantly used in the epilepsy literature but the definitions proposed differ considerably. It is used indifferently in a number of different settings: as a criterion for selection of patients eligible for new antiepileptic drug trials, for the selection of surgical candidates, for the design of epidemiological studies, for the design of studies on quality of life, for the definition of the epileptic encephalopathies (in comparison to more benign epilepsy syndromes), to mention but a few. As a result, available studies are usually not comparable and referral to epilepsy specialists is unacceptably delayed. The volume includes several focused chapters on all issues relating to drug-resistance and offers the basis for a consensus on a clinically meaningful core definition.

Epilepsy is one of most frequent neurological disorders affecting about 50 million people worldwide and 50% of them have at least another medical problem in comorbidity; sometimes this is a the cause of the epilepsy itself or it is due to shared neurobiological links between epilepsy and other medical conditions; other times it is a long-term consequence of the antiepileptic drug treatment. The Comorbidities of Epilepsy offers an up-to-date, comprehensive overview of all comorbidities of epilepsy (somatic, neurological and behavioral), by international authorities in the field of clinical epileptology, with an emphasis on epidemiology, pathophysiology, diagnosis and management. This book includes also a critical appraisal of the methodological aspects and limitations of current research on this field. Pharmacological issues in the management of comorbidities are discussed, providing information on drug dosages, side effects and interactions, in order to enable the reader to manage these patients safely. The Comorbidities of Epilepsy is aimed at all health professionals dealing with people with epilepsy including neurologists, epileptologists, psychiatrists, clinical psychologists, epilepsy specialist nurses and clinical researchers. Provides a comprehensive overview of somatic, neurological and behavioral co-morbidities of epilepsy Discusses up-to-date management of comorbidities of epilepsy Written by a group of international experts in the field

This volume highlights the recent advances in the understanding of the endocannabinoid system and the likely benefit from the therapeutic effects of cannabinoid treatment in a variety of health issues. Archeological evidence has shown that Cannabis has a long history of use for multiple purposes, including the treatment of medical conditions. The primary active constituent of the hemp plant Cannabis sativa, delta 9-tetrahydrocannabinol (Δ9-THC), causes euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concentration and impairment of memory, among other effects. Despite these undesirable effects, signaling is mostly inhibitory and suggests a putative role for cannabinoids as therapeutic agents by managing several diseases where inhibition of neurotransmitter release would be beneficial. The themes of this book have been edited and written by world-leaders in the field, The contents of the volume aims at readers from a range of academic and professional disciplines, such as biomedicine, several areas of biology, neurology, clinical medicine and pharmacy.